Join the Empagliflozin group to help and get support from people like you.
Empagliflozin News
Metformin, SGLT2 Inhibitors Exhibit Significantly Lower Dementia Risk
MONDAY, July 15, 2024 – Compared with other antidiabetic classes, metformin and sodium glucose co-transporter-2 inhibitors (SGLT2is) exhibit significantly lower dementia risk, according to a review...
ACC: Empagliflozin Does Not Cut Risk for Heart Failure After Acute MI
WEDNESDAY, April 10, 2024 – Empagliflozin does not reduce the risk for first hospitalization for heart failure or death among patients at increased risk for heart failure after acute myocardial...
ACC: Empagliflozin Cuts Heart Failure Hospitalization Risk After AMI
MONDAY, April 8, 2024 – For patients with acute myocardial infarction at risk for heart failure, empagliflozin reduces the risk for heart failure hospitalization, according to a study published...
Racial, Ethnic Differences Seen for Benefits of Antihyperglycemic Agents
THURSDAY, Sept. 28, 2023 – There are racial/ethnic differences in the cardiorenal effects of sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists...
US FDA Approves Jardiance for the Treatment of Adults with Chronic Kidney Disease
RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 22, 2023 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained ...
FDA Approves Jardiance (empagliflozin) for the Treatment of Type 2 Diabetes in Children 10 Years and Older
RIDGEFIELD, Conn. and INDIANAPOLIS, June 21, 2023 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along...
US FDA Approves Jardiance (empagliflozin) to Treat Adults with Heart Failure Regardless of Left Ventricular Ejection Fraction
RIDGEFIELD, Conn. and INDIANAPOLIS, Feb. 24, 2022 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death ...
FDA Approves Jardiance (empagliflozin) to Treat Adults Living with Heart Failure with Reduced Ejection Fraction
Ridgefield, Conn. and Indianapolis, August 18, 2021 – Jardiance (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death plus h...
FDA Approves Trijardy XR (empagliflozin/linagliptin/metformin) for Type 2 Diabetes in Adults
RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 27, 2020 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended...
FDA Medwatch Alert: SGLT2 (sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area
ISSUE: FDA is warning that cases of a rare but serious infection of the genitals and area around the genitals have been reported with the class of type 2 diabetes medicines called sodium-glucose...
FDA Approves Synjardy XR (empagliflozin/metformin hydrochloride extended-release) for Adults with Type 2 Diabetes
RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 12, 2016 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Synjardy XR (empagliflozin and metformin hydrochloride extended-release)...
FDA Approves Jardiance (empagliflozin) to Reduce Cardiovascular Death in Adults with Type 2 Diabetes
December 2, 2016 – The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2...
FDA Expands Indication For Type 2 Diabetes Treatment Synjardy (Empagliflozin/Metformin Hydrochloride) To Include Treatment-Naïve Adults
RIDGEFIELD, Conn., and INDIANAPOLIS, July 19, 2016 /PRNewswire/ – The U.S. Food and Drug Administration has approved an expanded indication for Synjardy (empagliflozin and metformin hydrochloride)...
FDA Medwatch Alert: SGLT2 Inhibitors: Drug Safety Communication - Labels to Include Warnings About Too Much Acid in the Blood and Serious Urinary Tract Infections
ISSUE: An FDA safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of...
FDA Medwatch Alert: Invokana and Invokamet (canagliflozin): Drug Safety Communication - New Information on Bone Fracture Risk and Decreased Bone Mineral Density
ISSUE: FDA has strengthened the warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures, and added new information about decreased...
Further information
Related condition support groups
Chronic Kidney Disease, Heart Failure, Congestive Heart Failure, Cardiovascular Risk Reduction, Diabetes, Type 2